The American Society of Hematology has named Roy L. Silverstein, MD, as its 2019 president. He will serve a year-long term through the end of December 2019.
Roy L. Silverstein, MD
Roy L. Silverstein, MD
The American Society of Hematology (ASH) has named Roy L. Silverstein, MD, as its 2019 president. He will serve a year-long term through the end of December 2019.
“Hematology is an exciting and rapidly moving discipline driven by research, innovation, and creative thinking in the clinic and in the laboratory,” said Silverstein, chairman of the department of medicine and associate director of the Medical College of Wisconsin Cancer Center. “I am delighted to serve as a leader of the organization that continues to move this field forward.”
During his presidency, Silverstein aims to develop new training programs and innovative pathways in the hematology space for clinicians and researchers. He hopes to accelerate entry into these careers.
Previously, Silverstein has served as the editor-in-chief for ASH’s news magazine,The Hematologist, chaired the Society’s Committee on Government Affairs, co-chaired the 2012 ASH Annual Meeting Scientific Program, and chaired search committees for ASH Clinical News and Blood Advances.
Silverstein is known for his research in platelet and vascular cell biology. His clinical interests include thrombosis, hemostasis, and myeloproliferative neoplasms. He also serves as a senior investigator at the Blood Research Institute at the BloodCenter of Wisconsin.
Connecting Spleen Volume Reduction to Survival Outcomes in MF
April 21st 2024During a Case-Based Roundtable® event, Raajit K. Rampal, MD, PhD, discussed the correlation between spleen volume responses and survival outcomes for patients with myelofibrosis in the second article of a 2-part series.
Read More
Savona Discusses First-Line JAK Inhibition for Patients With Myelofibrosis at Risk of Anemia
April 17th 2024During a Case-Based Roundtable® event, Michael Savona, MD, and participants discussed the case of a patient with myelofibrosis and moderate anemia receiving JAK inhibitor therapy.
Read More
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More
Scott Evaluates Treatment Options for Hydroxyurea-Resistant Polycythemia Vera
March 28th 2024In a Community Case Forum event in partnership with the Washington State Medical Oncology Society, Bart Scott, MD, broke down various trials of hydroxyurea, ruxolitinib, and interferon in patients with polycythemia vera to assess outcomes such as hematocrit control and molecular response.
Read More